Year: 2019
Type: review
Abstract: In contrast to prior belief, cancer cells require oxidative phosphorylation (OXPHOS) to strive, and exacerbated OXPHOS dependency frequently characterizes cancer stem cells, as well as primary or acquired resistance against chemotherapy or tyrosine kinase inhibitors. A growing arsenal of therapeutic agents is being designed to suppress the transfer of mitochondria from stromal to malignant cells, to interfere with mitochondrial biogenesis, to directly inhibit respiratory chain complexes, or to disrupt mitochondrial function in other ways. For the experimental treatment of cancers, OXPHOS inhibitors can be advantageously combined with tyrosine kinase inhibitors, as well as with other strategies to inhibit glycolysis, thereby causing a lethal energy crisis. Unfortunately, most of the preclinical data arguing in favor of OXPHOS inhibition have been obtained in xenograft models, in which human cancer cells are implanted in immunodeficient mice. Future studies on OXPHOS inhibitors should elaborate optimal treatment schedules and combination regimens that stimulate-or at least are compatible with-anticancer immune responses for long-term tumor control.
Source: International Journal of Cancer
DOI: 10.1002/ijc.32616
Institutions: Inserm, Institut Gustave Roussy, Sorbonne Université, Centre de Recherche des Cordeliers, La Ligue Contre le Cancer, Immunité et Cancer, Karolinska University Hospital, Chinese Academy of Sciences, Karolinska Institutet, Hôpital Européen Georges-Pompidou, Suzhou Institute of Systems Medicine
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: oxidative phosphorylation, OXPHOS inhibitors, cancer therapy, cancer stem cells, mitochondrial biogenesis, mitochondrial transfer, electron transport inhibition, chemoresistance, tyrosine kinase inhibitors, glycolysis inhibition, energy crisis, combination therapy, xenograft models, antitumor immunity
Open Access status: bronze
Funders: Bristol-Myers Squibb Foundation, Bristol-Myers Squibb, Association pour la Recherche sur le Cancer, Seerave Foundation, E-Rare, NuCana, European Commission, Bayer HealthCare, Agence Nationale de la Recherche, Fondation Leducq, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Ligue Contre le Cancer, Institut Universitaire de France, Institut National Du Cancer, Institut Gustave-Roussy, PharmaMar, Institut Mérieux, European Research Area Network on Cardiovascular Diseases, High-end Foreign Experts Recruitment Plan of China, Labex Immuno-Oncology
OpenAlex ID: W2968141411
